Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1945 29
1946 109
1947 139
1948 147
1949 155
1950 242
1951 295
1952 280
1953 344
1954 401
1955 326
1956 490
1957 702
1958 768
1959 743
1960 570
1961 604
1962 641
1963 993
1964 1327
1965 1021
1966 1185
1967 1435
1968 1900
1969 2087
1970 2145
1971 2348
1972 2513
1973 2542
1974 2667
1975 2486
1976 2574
1977 2536
1978 2559
1979 2868
1980 3010
1981 2982
1982 3121
1983 3219
1984 3362
1985 3329
1986 3296
1987 3209
1988 3453
1989 3517
1990 3741
1991 3788
1992 3835
1993 3991
1994 3997
1995 3994
1996 4053
1997 4340
1998 4357
1999 4368
2000 4794
2001 4917
2002 5509
2003 5604
2004 6097
2005 6682
2006 7322
2007 7810
2008 8103
2009 8790
2010 8977
2011 9140
2012 9788
2013 10059
2014 10408
2015 10518
2016 10595
2017 10708
2018 10473
2019 10537
2020 11121
2021 11227
2022 11066
2023 10342
2024 11203
2025 11278
2026 4760

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

324,348 results

Results by year

Filters applied: . Clear all
Page 1
Individualized treatment of diabetes mellitus in older adults.
Araki A. Araki A. Geriatr Gerontol Int. 2024 Dec;24(12):1257-1268. doi: 10.1111/ggi.14979. Epub 2024 Oct 7. Geriatr Gerontol Int. 2024. PMID: 39375857 Free PMC article. Review.
To prevent frailty or sarcopenia, optimal energy intake, adequate protein and vitamin intake, and resistance or multi-component exercise are recommended. For hypoglycemic drug therapy, it is important to reduce hypoglycemia, to use sodium glucose cotransporter-2 (SG …
To prevent frailty or sarcopenia, optimal energy intake, adequate protein and vitamin intake, and resistance or multi-component exercise are …
The effects of aerobic exercise combined with resistance training on inflammatory factors and heart rate variability in middle-aged and elderly women with type 2 diabetes mellitus.
Su X, He J, Cui J, Li H, Men J. Su X, et al. Ann Noninvasive Electrocardiol. 2022 Nov;27(6):e12996. doi: 10.1111/anec.12996. Epub 2022 Jul 27. Ann Noninvasive Electrocardiol. 2022. PMID: 35894768 Free PMC article. Clinical Trial.
The control group was treated with routine hypoglycemic drugs, while the exercise group was treated with routine hypoglycemic drugs + resistance training (AE + RT). ...The time-domain indexes, i.e., SDNN and RMSSD, as well as the frequency domain index, i.e., (lnhf) …
The control group was treated with routine hypoglycemic drugs, while the exercise group was treated with routine hypoglycemic …
Gender differences in new hypoglycemic drug effects on renal outcomes: a systematic review.
Gembillo G, Cernaro V, Giuffrida AE, Russo G, Giandalia A, Siligato R, Longhitano E, Santoro D. Gembillo G, et al. Expert Rev Clin Pharmacol. 2022 Mar;15(3):323-339. doi: 10.1080/17512433.2022.2055546. Epub 2022 Apr 6. Expert Rev Clin Pharmacol. 2022. PMID: 35300556
EXPERT OPINION: New hypoglycemic drugs represent promising tools in the treatment and prevention of severe complications of diabetes, cardiovascular diseases and chronic kidney disease. ...Our systematic review demonstrated that the gap among sexes in DKD can be partially …
EXPERT OPINION: New hypoglycemic drugs represent promising tools in the treatment and prevention of severe complications of diabetes, …
Comparative cardiovascular outcomes and safety of hypoglycemic drug classes in patients with type 2 diabetes and hypertension: a multicenter cohort analysis.
Wei Z, Xu W, Wang Y, Tian Y, Wang Z, Jing S, Liu W, Shen S, Qin C, Zhang X, Li J, Liu Y. Wei Z, et al. Cardiovasc Diabetol. 2025 Aug 20;24(1):343. doi: 10.1186/s12933-025-02892-5. Cardiovasc Diabetol. 2025. PMID: 40836299 Free PMC article.
However, real-world evidence comparing the CV effectiveness and safety of major hypoglycemic drug classes remains limited in this population. This multicenter pooled analysis aims to directly compare the CV outcomes and safety profiles of these key agents in …
However, real-world evidence comparing the CV effectiveness and safety of major hypoglycemic drug classes remains limited in t …
Tirzepatide as a novel effective and safe strategy for treating obesity: a systematic review and meta-analysis of randomized controlled trials.
Cai W, Zhang R, Yao Y, Wu Q, Zhang J. Cai W, et al. Front Public Health. 2024 Jan 31;12:1277113. doi: 10.3389/fpubh.2024.1277113. eCollection 2024. Front Public Health. 2024. PMID: 38356942 Free PMC article.
OBJECTIVE: To systematically evaluate the efficacy and safety of a new hypoglycemic drug, tirzepatide, for treating obesity based on indicators such as BMI, waist circumference, and body weight. ...CONCLUSION: Tirzepatide, as a weight loss drug, significantly …
OBJECTIVE: To systematically evaluate the efficacy and safety of a new hypoglycemic drug, tirzepatide, for treating obesity ba …
Emergency management of oral hypoglycemic drug toxicity.
Rowden AK, Fasano CJ. Rowden AK, et al. Emerg Med Clin North Am. 2007 May;25(2):347-56; abstract viii. doi: 10.1016/j.emc.2007.02.010. Emerg Med Clin North Am. 2007. PMID: 17482024 Review.
These different classes have various mechanisms of action, giving each class a unique potential for toxicity that necessitates a distinct approach to evaluation, treatment, and disposition of each class of drug. The practicing emergency physician must have an understanding …
These different classes have various mechanisms of action, giving each class a unique potential for toxicity that necessitates a distinct ap …
Metformin.
Stumvoll M, Häring HU, Matthaei S. Stumvoll M, et al. Endocr Res. 2007;32(1-2):39-57. doi: 10.1080/07435800701743828. Endocr Res. 2007. PMID: 18271504 Review. No abstract available.
Gliclazide.
Al-Omary FAM. Al-Omary FAM. Profiles Drug Subst Excip Relat Methodol. 2017;42:125-192. doi: 10.1016/bs.podrm.2017.02.003. Epub 2017 Apr 12. Profiles Drug Subst Excip Relat Methodol. 2017. PMID: 28431776
Gliclazide is a second-generation oral hypoglycemic drug used for the treatment of noninsulin-dependent diabetes mellitus. It belongs to the sulfonylurea class that stimulates insulin secretion from pancreatic beta-cells by inhibiting ATP-dependent potassium channel …
Gliclazide is a second-generation oral hypoglycemic drug used for the treatment of noninsulin-dependent diabetes mellitus. It …
Glipizide: an oral hypoglycemic drug.
Wensing G. Wensing G. Am J Med Sci. 1989 Jul;298(1):69-71. doi: 10.1097/00000441-198907000-00012. Am J Med Sci. 1989. PMID: 2665487 Review. No abstract available.
Hypoglycemic drug liraglutide alleviates low muscle mass by inhibiting the expression of MuRF1 and MAFbx in diabetic muscle atrophy.
Fan D, Wang Y, Liu B, Yin F. Fan D, et al. J Chin Med Assoc. 2023 Feb 1;86(2):166-175. doi: 10.1097/JCMA.0000000000000807. Epub 2022 Oct 24. J Chin Med Assoc. 2023. PMID: 36279106 Free PMC article.
BACKGROUND: Low muscle mass, that is, muscular atrophy, is an independent risk factor for type 2 diabetes mellitus (T2DM). Few studies investigated whether hypoglycemic drugs can alleviate low muscle mass and related mechanisms. METHODS: This study recruited 51 type 2 diab …
BACKGROUND: Low muscle mass, that is, muscular atrophy, is an independent risk factor for type 2 diabetes mellitus (T2DM). Few studies inves …
324,348 results
You have reached the last available page of results. Please see the User Guide for more information.